Focused On-demand Library for Eukaryotic initiation factor 4A-II

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q14240

UPID:

IF4A2_HUMAN

Alternative names:

ATP-dependent RNA helicase eIF4A-2

Alternative UPACC:

Q14240; D3DNU9; Q53XJ6; Q96B90; Q96EA8

Background:

Eukaryotic initiation factor 4A-II (eIF4A-II) is a pivotal ATP-dependent RNA helicase, serving as a crucial component of the eIF4F complex, instrumental in cap recognition and mRNA ribosomal binding. This protein plays a vital role in unwinding RNA secondary structures in the 5'-UTR of mRNAs, facilitating the small ribosomal subunit's binding and scanning for the initiator codon, essential for the translation initiation process.

Therapeutic significance:

Understanding the role of Eukaryotic initiation factor 4A-II could open doors to potential therapeutic strategies.